Nucleis, RNAx Ink shRNA Technology Co-Marketing Deal
Nucleis, which develops custom transgenic mice, has signed a deal to co-market in vitro and in vivo shRNA validation technology with RNAx, the companies said this week.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Browse our free articlesYou can still register for access to our free content.